GLP1R and obesity disorder: Exaggerated incretin hormone release following bariatric surgery contributes to the beneficial outcomes of weight loss [10] and glycaemic control [11] and mimetics of GLP-1 are effective treatments for Type 2 diabetes [12], with some agents additionally licenced to treat obesity.